NIOX® FeNO testing

Asthma and airway inflammation

Asthma is a common lung disease that affects 235 million people worldwide. It is the world’s most frequent chronic disease among children, and WHO estimates that the number of people with asthma will increase by more than 100 million by 2025.

The disease is characterized by chronically inflamed airways, which can be irritated by external triggers, such as allergens, tobacco smoke, cold air, chest infections and certain chemicals. This can cause airway contraction and secretion of mucus into the airways, making breathing more difficult. Consequently, asthma can result in symptoms such as coughing, wheezing, breathlessness and chest tightness. Asthma exacerbations occur when the number and / or level of symptoms increase and become more intense. Severe asthma exacerbations can require emergency care, and can even be fatal.

Nitric oxide and inflammation

Nitric oxide is released by epithelial cells in the bronchial wall of the lungs. When the airways are inflamed due to allergic asthma the level of nitric oxide is increased. Scientists at the Karolinska Institute in Sweden discovered that the proportion of nitric oxide present in patients’ breath provides a direct measure of underlying allergic airway inflammation. As a result, fractional exhaled nitric oxide (FeNO) is now established as a robust, non-invasive biomarker of allergic airway inflammation.

NIOX® FeNO testing

Circassia’s innovative NIOX® technology provides standardized FeNO measurements using simple-to-use, point-of-care devices. The technology is highly reliable, providing rapid analysis of FeNO levels at an accuracy of ±5 parts per billion (or 10% maximum). As a result, our NIOX® technology is used around the world to assist the diagnosis and management of airway inflammation associated with asthma. In particular, FeNO testing is used to determine patients’ response to inhaled corticosteroid treatment, tailoring corticosteroid therapy and monitoring compliance.

Visit the NIOX website for more details on our NIOX® FeNO testing.

US Use and Risks Statement

NIOX VERO® is a portable system for the non-invasive, quantitative, simple and safe measurement of Nitric Oxide (NO) in human breath. Nitric Oxide is frequently increased in some inflammatory processes such as asthma. FeNO measurements provide the physician with means of evaluating an asthma patient’s response to anti-inflammatory therapy, as an adjunct to the established clinical and laboratory assessments in asthma. The NIOX VERO is intended for prescription use and should only be used as directed in the NIOX VERO User Manual by trained healthcare professionals. NIOX VERO is suitable for children, approximately 7 – 17 years, and adults 18 years and older.  NIOX VERO cannot be used with infants or by children approximately under the age of 7, as measurement requires patient cooperation. NIOX VERO should not be used in critical care, emergency care or in anaesthesiology